Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of the SHOX2 / PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease

9 Sept 2016

Abstract excerpt

INTRODUCTION: Low-dose computed tomography (LDCT) is used for screening for lung cancer (LC) in high-risk patients in the United States. The definition of high risk and the impact of frequent false-positive results of low-dose computed tomography remains a challenge. DNA methylation biomarkers are valuable noninvasive diagnostic tools for cancer detection. This study reports on the evaluation of methylation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27544059
DOI: 10.1016/j.jtho.2016.08.123

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of the SHOX2 / PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung DiseasePMID 27544059Read ↗

A Panel of DNA Methylation Biomarkers for Detection and Improving Diagnostic Efficiency of Lung CancerSemantic proximity Read ↗

A novel multimodal prediction model based on DNA methylation biomarkers and low-dose computed tomography images for identifying early-stage lung cancerSemantic proximity Read ↗

DNA methylation analysis in plasma for early diagnosis in lung adenocarcinomaSemantic proximity Read ↗

Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta‐analysis updateSemantic proximity Read ↗

A systematic review and meta analysis of the valve of SHOX2 and RASSF1A gene methylation in bronchial elveslar lavage fluid in the diagnosis of lung cancerSemantic proximity Read ↗

DNA Methylation Analysis of the SHOX2 and RASSF1A Panel Using Cell-Free DNA in the Diagnosis of Malignant Pleural EffusionSemantic proximity Read ↗

The value of SHOX2 methylation test in peripheral blood samples used for the differential diagnosis of lung cancer and other lung disordersSemantic proximity Read ↗

Diagnostic performance of RASSF1A and SHOX2 methylation combined with EGFR mutations for differentiation between small pulmonary nodules.Semantic proximity Read ↗

A combined model of circulating tumor DNA methylated SHOX2/SCT/HOXA7 and clinical features facilitates the discrimination of malignant from benign pulmonary nodulesSemantic proximity Read ↗

Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinomaSemantic proximity Read ↗

Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypesSemantic proximity Read ↗

Detection of the DNA methylation of seven genes contribute to the early diagnosis of lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.